loading

Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스

pulisher
07:30 AM

BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus

07:30 AM
pulisher
07:17 AM

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus

07:17 AM
pulisher
07:01 AM

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

07:01 AM
pulisher
07:00 AM

BioCryst Expands Team with 7 Strategic Hires, Grants 47,250 Restricted Stock Units - Stock Titan

07:00 AM
pulisher
12:59 PM

BioCryst stock soars to 52-week high, hits $11.14 - Investing.com India

12:59 PM
pulisher
Jun 02, 2025

BioCryst stock soars to 52-week high, hits $11.14 By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

BioCryst to Present New Data at 2025 Meeting of the European Aca - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire Inc.

Jun 02, 2025
pulisher
May 30, 2025

BioCryst (BCRX) Highlights Positive Data on Berotralstat for HAE Treatment | BCRX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotrals - GuruFocus

May 30, 2025
pulisher
May 30, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages | BCRX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

BioCryst reports efficacy of HAE drug across age groups - Investing.com

May 30, 2025
pulisher
May 30, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

BCRXBiocryst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

May 30, 2025
pulisher
May 28, 2025

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Drugmaker targets younger patients as revenue balloons - The Business Journals

May 28, 2025
pulisher
May 28, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

May 28, 2025
pulisher
May 27, 2025

BioCryst to Present at Upcoming Investor Conferences | BCRX Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

BioCryst to Present at Upcoming Investor Conferences - The Manila Times

May 27, 2025
pulisher
May 27, 2025

How To Trade (BCRX) - news.stocktradersdaily.com

May 27, 2025
pulisher
May 27, 2025

Bank of America Corp DE Sells 261,127 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 27, 2025
pulisher
May 26, 2025

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade - Yahoo Finance

May 26, 2025
pulisher
May 23, 2025

BioCryst Pharmaceuticals Inc (BCRX) Trading 3.62% Higher on May 22 - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Orladeyo reduces swelling rates in severe HAE: Real-world data - Angioedema News

May 22, 2025
pulisher
May 22, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded by StockNews.com to Strong-Buy Rating - Defense World

May 22, 2025
pulisher
May 21, 2025

Transcript : BioCryst Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

D. E. Shaw & Co. Inc. Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 21, 2025
pulisher
May 20, 2025

BioCryst's Orladeyo up for FDA review in pediatric HAE patients - MSN

May 20, 2025
pulisher
May 20, 2025

BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid Orladeyo success, pipeline progress - Investing.com Nigeria

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 19, 2025
pulisher
May 19, 2025

Ameriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 19, 2025
pulisher
May 18, 2025

Best Momentum Stocks to Buy for May 9th - The Globe and Mail

May 18, 2025
pulisher
May 17, 2025

BioCryst reports ORLADEYO reduces severe HAE attack rates By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Cut to Buy at StockNews.com - Defense World

May 17, 2025
pulisher
May 16, 2025

(BCRX) Long Term Investment Analysis - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

BioCryst reports ORLADEYO reduces severe HAE attack rates - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

BioCryst Presents New Real-world Evidence Showing Significant an - GuruFocus

May 16, 2025
pulisher
May 16, 2025

BioCryst (BCRX) Highlights Significant HAE Attack Reductions with ORLADEYO | BCRX Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewswire

May 16, 2025
pulisher
May 16, 2025

New Clinical Evidence: ORLADEYO Dramatically Reduces HAE Attacks in Both Teens and Severe Patients - Stock Titan

May 16, 2025
pulisher
May 15, 2025

FDA to review Orladeyo application for young children with HAE - Angioedema News

May 15, 2025
pulisher
May 15, 2025

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE - Yahoo

May 15, 2025
pulisher
May 15, 2025

The Manufacturers Life Insurance Company Sells 195,621 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 15, 2025
pulisher
May 14, 2025

BioCryst (BCRX) Gains FDA Priority Review for Pediatric ORLADEYO - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan

May 14, 2025
pulisher
May 14, 2025

FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years - Contemporary Pediatrics

May 14, 2025
pulisher
May 14, 2025

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients - Contemporary Pediatrics

May 14, 2025
pulisher
May 14, 2025

BioCryst’s ORLADEYO Receives FDA Priority Review - TipRanks

May 14, 2025
pulisher
May 14, 2025

Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

FDA Fast-Tracks First-Ever Oral HAE Treatment for Children Under 12: September Decision Expected - Stock Titan

May 14, 2025
pulisher
May 11, 2025

BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN

May 11, 2025
pulisher
May 10, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $11.00 - Defense World

May 10, 2025
pulisher
May 09, 2025

Best Momentum Stocks To Buy For May 9th - Barchart.com

May 09, 2025
pulisher
May 09, 2025

New Strong Buy Stocks for May 9th - The Globe and Mail

May 09, 2025
$8.425
price down icon 3.28%
drug_manufacturers_specialty_generic RDY
$14.62
price down icon 0.81%
$124.86
price down icon 0.01%
drug_manufacturers_specialty_generic HCM
$14.21
price up icon 2.99%
$324.39
price down icon 0.70%
$17.29
price up icon 0.03%
자본화:     |  볼륨(24시간):